Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 334

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 334
---
including accounting or financial policies) or practices.

On May 30, 2023, the Iris Board held a meeting and: (i) extended the date by which Iris must consummate a Business Combination for a three month period from June 9, 2023 to September 9, 2023, and (ii) appointed Nicholas Fernandez to serve as a director. Consistent with this extension by the Iris Board, the parties to the Business Combination Agreement amended the Business Combination Agreement on June 1, 2023, to extend the date by which the parties thereto can terminate the Business Combination Agreement if the transaction has not closed by that date from June 7, 2023, to September 30, 2023.

On August 16, 2023, Iris filed a preliminary proxy statement with the SEC containing a proposal to stockholders to amend the Iris Certificate of Incorporation to, among other things, extend the date by which Iris must consummate a business combination from September 9, 2023, to March 9, 2024. On August 14, 2023, the parties to the Business Combination Agreement amended the Business Combination Agreement to extend the Outside Date from September 30, 2023 to March 9, 2024.

On September 7, 2023, the Company filed with the Secretary of State of the State of Delaware an amendment to the Iris Certificate of Incorporation to: (i) change the date by which the Company must consummate a business combination from September 9, 2023 to December 9, 2023 (subject to an additional three month extension at the discretion of the Iris Board); (ii) to remove from the charter the limitation on share repurchases prior to the consummation of a business combination that would cause the Company’s net tangible assets to be less than $5,000,001 following such repurchases, and the limitation that the Company shall not consummate a business combination if it would cause the Company’s net tangible assets to be less than $5,000,001 either immediately prior or subsequent to the consummation of such business combination; and (iii) to amend the charter to provide for the right of a holder of shares of the Class B common stock of the Company, par value $0.0001 per share, to convert such shares into shares of the Iris Class A Common Stock on a one-for-one basis prior to the closing of a business combination. The Company’s stockholders approved the amendments